Title | Drug Evaluation in Angina Pectoris [electronic resource] / edited by Diego Ardissino, Lionel H. Opie, Stefano Savonitto |
---|---|
Imprint | Boston, MA : Springer US : Imprint: Springer, 1994 |
Connect to | http://dx.doi.org/10.1007/978-1-4615-2628-5 |
Descript | XVI, 262 p. online resource |
I. Pathophysiology, Clinical Presentation, and Prognosis of Angina Pectoris -- 1. Pathophysiology, Clinical Presentation, and Prognosis of Angina Pectoris -- II. Evaluation of the Patient with Angina Pectoris -- 2. Clinical Value of Anginal Symptoms and their Assessment in Drug Trials -- 3. Quality of Life Assessments in Clinical Trials of Angina Pectoris -- 4. Optimizing the Exercise Test for Pharmacological Studies in Patients with Angina Pectoris -- 5. Evaluation of Transient Myocardial Ischemia by Holtet Monitoring -- 6. Radionuclide Methods for the Evaluation of Ventricular Function and Thrombolytic Therapy -- 7. Provocative Testing of Coronary Vasoconstriction -- 8. Pharmacological Investigation Using Invasive Methods -- III. Planning, Conducting, and Evaluating Clinical Trials in Angina Pectoris -- 9. Patient Selection and Definition of Study Endpoints -- 10. Controlling Potential Sources of Bias in Clinical Trials of Antianginal Agents -- 11. Parallel-Group and Crossover Designs for Drug Evaluation in the Various Forms of Angina Pectoris -- 12. Dose-Response Relationships and Combination Studies with Antianginal Agents -- 13. Sample Size and Power of Clinical Trials -- 14. Multicenter Trials: Design and Conduct -- IV. Critical Issues Related to Specific Antianginal Agents -- 15. Experimental Evaluation and Clinical Relevance of Tolerance to Nitrates -- 16. Clinical Evaluation of Beta-blockers in Various Forms of Angina Pectoris -- 17. Efficacy and Safety of Calcium Antagonists as Antianginal Agents -- 18. Effects of Antithrombotic Agents on Mortality and Nonfatal Cardiac Events -- 19. The Challenge of Thrombolytic Therapy in Unstable Angina Pectoris -- V. Regulatory Aspects Related to the Evaluation of New Antianginal Agents -- 20. Comments on the Food and Drug Administration (FDA) Cardiac and Renal Drugs Advisory Committee Recommended Guidelines for the Conduct of Antianginal Drug Trials -- 21. European Communitiesโ Committee for Proprietary Medicinal Products (CPMP) Working Party on Efficacy of Medicinal Products